Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

Apostolia M. Tsimberidou, Elihu Estey, Jorge E. Cortes, Guillermo Garcia-Manero, Stefan Faderl, Srdan Verstovsek, Deborah A. Thomas, Alessandra Ferrajoli, Michael J. Keating, Susan O'Brien, Hagop M. Kantarjian, Francis J. Giles

Research output: Contribution to journalArticle

Abstract

Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Its role as a component of post-remission therapy in AML has not been established. The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens. Methods: The MFAC regimen comprised: Mylotarg 4.5 mg/m2 intravenously (i.v.) over 2 h after a loading dose of cyclosporine A (CSA) on day 1; fludarabine 15 mg/m2 i.v. over 30 min every 12 h for six doses on days 2 through 4; ara-C 0.5 g/m over 2 h every 12 h for six doses on days 2 through 4, 4 h after fludarabine started; CSA 6 mg/kg over 2 h, followed by 16 mg/kg continuous i.v. infusion on days 1 and 2. Patients in complete remission (CR) commenced idarubicin and araC (IA) alternating with MFAC or vice versa for 9 months from the date of CR. Idarubicin was administered at 8 mg/m2 on days 1 and 2 and ara-C at 1.5 g/m2 on days 1 and 2. Results: A total of 22 patients received 76 courses of MFAC (35 courses) alternating with IA (41 courses) or vice versa. The interval between courses, and degrees of myelosuppression, were equivalent in the alternating regimens. Failure-free and 12-month survival rates of were 32% and 55%, respectively. Grade 3/4 toxicities, including sepsis, neutropenic fever, and nausea/vomiting, were equivalent with MFAC and IA. Conclusions: Post-remission therapy with MFAC is feasible and well tolerated in patients with AML.

Original languageEnglish (US)
Pages (from-to)449-452
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume52
Issue number6
DOIs
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Cytarabine
Acute Myeloid Leukemia
Cyclosporine
Idarubicin
Therapeutics
Antibodies, Monoclonal, Humanized
fludarabine
gemtuzumab
Nausea
Vomiting
Toxicity
Anti-Idiotypic Antibodies
Sepsis
Fever
Survival Rate
Anti-Bacterial Agents
Antibodies

Keywords

  • Cytarabine
  • Idarubicin
  • Mylotarg
  • Post-remission therapy

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. / Tsimberidou, Apostolia M.; Estey, Elihu; Cortes, Jorge E.; Garcia-Manero, Guillermo; Faderl, Stefan; Verstovsek, Srdan; Thomas, Deborah A.; Ferrajoli, Alessandra; Keating, Michael J.; O'Brien, Susan; Kantarjian, Hagop M.; Giles, Francis J.

In: Cancer Chemotherapy and Pharmacology, Vol. 52, No. 6, 01.12.2003, p. 449-452.

Research output: Contribution to journalArticle

Tsimberidou, AM, Estey, E, Cortes, JE, Garcia-Manero, G, Faderl, S, Verstovsek, S, Thomas, DA, Ferrajoli, A, Keating, MJ, O'Brien, S, Kantarjian, HM & Giles, FJ 2003, 'Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia', Cancer Chemotherapy and Pharmacology, vol. 52, no. 6, pp. 449-452. https://doi.org/10.1007/s00280-003-0671-3
Tsimberidou, Apostolia M. ; Estey, Elihu ; Cortes, Jorge E. ; Garcia-Manero, Guillermo ; Faderl, Stefan ; Verstovsek, Srdan ; Thomas, Deborah A. ; Ferrajoli, Alessandra ; Keating, Michael J. ; O'Brien, Susan ; Kantarjian, Hagop M. ; Giles, Francis J. / Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. In: Cancer Chemotherapy and Pharmacology. 2003 ; Vol. 52, No. 6. pp. 449-452.
@article{590a68e192974b66be550443600f98a0,
title = "Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia",
abstract = "Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Its role as a component of post-remission therapy in AML has not been established. The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens. Methods: The MFAC regimen comprised: Mylotarg 4.5 mg/m2 intravenously (i.v.) over 2 h after a loading dose of cyclosporine A (CSA) on day 1; fludarabine 15 mg/m2 i.v. over 30 min every 12 h for six doses on days 2 through 4; ara-C 0.5 g/m over 2 h every 12 h for six doses on days 2 through 4, 4 h after fludarabine started; CSA 6 mg/kg over 2 h, followed by 16 mg/kg continuous i.v. infusion on days 1 and 2. Patients in complete remission (CR) commenced idarubicin and araC (IA) alternating with MFAC or vice versa for 9 months from the date of CR. Idarubicin was administered at 8 mg/m2 on days 1 and 2 and ara-C at 1.5 g/m2 on days 1 and 2. Results: A total of 22 patients received 76 courses of MFAC (35 courses) alternating with IA (41 courses) or vice versa. The interval between courses, and degrees of myelosuppression, were equivalent in the alternating regimens. Failure-free and 12-month survival rates of were 32{\%} and 55{\%}, respectively. Grade 3/4 toxicities, including sepsis, neutropenic fever, and nausea/vomiting, were equivalent with MFAC and IA. Conclusions: Post-remission therapy with MFAC is feasible and well tolerated in patients with AML.",
keywords = "Cytarabine, Idarubicin, Mylotarg, Post-remission therapy",
author = "Tsimberidou, {Apostolia M.} and Elihu Estey and Cortes, {Jorge E.} and Guillermo Garcia-Manero and Stefan Faderl and Srdan Verstovsek and Thomas, {Deborah A.} and Alessandra Ferrajoli and Keating, {Michael J.} and Susan O'Brien and Kantarjian, {Hagop M.} and Giles, {Francis J.}",
year = "2003",
month = "12",
day = "1",
doi = "10.1007/s00280-003-0671-3",
language = "English (US)",
volume = "52",
pages = "449--452",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

AU - Tsimberidou, Apostolia M.

AU - Estey, Elihu

AU - Cortes, Jorge E.

AU - Garcia-Manero, Guillermo

AU - Faderl, Stefan

AU - Verstovsek, Srdan

AU - Thomas, Deborah A.

AU - Ferrajoli, Alessandra

AU - Keating, Michael J.

AU - O'Brien, Susan

AU - Kantarjian, Hagop M.

AU - Giles, Francis J.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Its role as a component of post-remission therapy in AML has not been established. The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens. Methods: The MFAC regimen comprised: Mylotarg 4.5 mg/m2 intravenously (i.v.) over 2 h after a loading dose of cyclosporine A (CSA) on day 1; fludarabine 15 mg/m2 i.v. over 30 min every 12 h for six doses on days 2 through 4; ara-C 0.5 g/m over 2 h every 12 h for six doses on days 2 through 4, 4 h after fludarabine started; CSA 6 mg/kg over 2 h, followed by 16 mg/kg continuous i.v. infusion on days 1 and 2. Patients in complete remission (CR) commenced idarubicin and araC (IA) alternating with MFAC or vice versa for 9 months from the date of CR. Idarubicin was administered at 8 mg/m2 on days 1 and 2 and ara-C at 1.5 g/m2 on days 1 and 2. Results: A total of 22 patients received 76 courses of MFAC (35 courses) alternating with IA (41 courses) or vice versa. The interval between courses, and degrees of myelosuppression, were equivalent in the alternating regimens. Failure-free and 12-month survival rates of were 32% and 55%, respectively. Grade 3/4 toxicities, including sepsis, neutropenic fever, and nausea/vomiting, were equivalent with MFAC and IA. Conclusions: Post-remission therapy with MFAC is feasible and well tolerated in patients with AML.

AB - Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Its role as a component of post-remission therapy in AML has not been established. The Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen was evaluated in patients in complete remission following Mylotarg-containing regimens. Methods: The MFAC regimen comprised: Mylotarg 4.5 mg/m2 intravenously (i.v.) over 2 h after a loading dose of cyclosporine A (CSA) on day 1; fludarabine 15 mg/m2 i.v. over 30 min every 12 h for six doses on days 2 through 4; ara-C 0.5 g/m over 2 h every 12 h for six doses on days 2 through 4, 4 h after fludarabine started; CSA 6 mg/kg over 2 h, followed by 16 mg/kg continuous i.v. infusion on days 1 and 2. Patients in complete remission (CR) commenced idarubicin and araC (IA) alternating with MFAC or vice versa for 9 months from the date of CR. Idarubicin was administered at 8 mg/m2 on days 1 and 2 and ara-C at 1.5 g/m2 on days 1 and 2. Results: A total of 22 patients received 76 courses of MFAC (35 courses) alternating with IA (41 courses) or vice versa. The interval between courses, and degrees of myelosuppression, were equivalent in the alternating regimens. Failure-free and 12-month survival rates of were 32% and 55%, respectively. Grade 3/4 toxicities, including sepsis, neutropenic fever, and nausea/vomiting, were equivalent with MFAC and IA. Conclusions: Post-remission therapy with MFAC is feasible and well tolerated in patients with AML.

KW - Cytarabine

KW - Idarubicin

KW - Mylotarg

KW - Post-remission therapy

UR - http://www.scopus.com/inward/record.url?scp=10744224798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744224798&partnerID=8YFLogxK

U2 - 10.1007/s00280-003-0671-3

DO - 10.1007/s00280-003-0671-3

M3 - Article

C2 - 13680159

AN - SCOPUS:10744224798

VL - 52

SP - 449

EP - 452

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -